Delcath Systems, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCTH research report →
Range $25 – $32
Price Chart
About the company
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver.
- CEO
- Gerard J. Michel
- IPO
- 2018
- Employees
- 156
- HQ
- Queensbury, NY, US
Get TickerSpark's AI analysis on DCTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $653.67M
- P/E
- 108.09
- Fwd P/E
- 106.29
- PEG
- 0.06
- P/S
- 6.09
- P/B
- 5.20
- EV/EBITDA
- 66.30
- Div Yield
- 0.00%
- Gross Margin
- 87.59%
- Op Margin
- 5.17%
- Net Margin
- 6.05%
- ROE
- 5.56%
- ROIC
- 3.13%
Latest fiscal year · YoY change
- Revenue
- $85.23M+129.1%
- Gross Profit
- $73.43M+136.8%
- Op Income
- $660.00K
- Net Income
- $2.70M+110.2%
- EPS
- $0.08+108.6%
- OCF Growth
- +220.5%
- FCF Growth
- +209.0%
- 52W High
- $22.51
- 52W Low
- $8.48
- 50D MA
- $16.22
- 200D MA
- $12.95
- Beta
- 0.60
- RSI (14)
- 58
- Avg Volume
- 497.48K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Delcath delivered a record third quarter driven by rapid HEPZATO KIT adoption, strong cash generation, and raised full-year revenue guidance.· November 9, 2026
- Q3 revenue hit a record $35.1 million, up 71% year over year, led by HEPZATO KIT and a 72% increase in HEPZATO volume.
- Gross margin remained very high at 89%, and the company generated $8.2 million of operating cash in the quarter with $104.3 million in cash and investments and no debt.
- Management raised full-year 2026 revenue guidance to $115 million-$117 million and expects at least 41% HEPZATO KIT volume growth for the year.
- The U.S. treatment network expanded to 33 active centers, with management expecting at least 36 by year-end if planned activations proceed.
- Clinical pipeline updates were mixed: colorectal interim data is now expected around Q2/Q3 next year, while breast cancer enrollment remains slower than planned.
Delcath reported third-quarter 2026 total revenue of $35.1 million, versus $20.6 million in Q3 2025. HEPZATO KIT revenue was $32.7 million, up from $19.3 million a year ago, and CHEMOSAT revenue was $2.4 million versus $1.3 million. Gross margin was 89%, compared with 87% in Q3 2025. Net income was $7 million, up from $0.8 million, and adjusted EBITDA was $11.5 million versus $5.3 million. Cash generated from operations was $8.2 million, compared with $4.8 million last year, and the company ended the quarter with $104.3 million in cash and investments and no debt. For 2026, management raised total revenue guidance to $115 million-$117 million, expects at least 41% HEPZATO KIT volume growth, and sees Q4 revenue of $25.8 million-$27.8 million, implying about 25% to 34% year-over-year growth. Full-year gross margin is expected to be 87% to 89%, with positive adjusted EBITDA.
Gerard Michel said the quarter reflected growing adoption of HEPZATO KIT and cited several drivers of stronger utilization: combination therapy becoming more standard, patients arriving better informed, fewer clinical-trial headwinds than last year, and better center staffing/capacity. He emphasized that once centers gain experience and see results, the therapy becomes part of standard care, and pointed to the 1,000th commercial U.S. HEPZATO treatment as a sign of broader acceptance. His tone was upbeat but measured, especially on pipeline timing, where he said colorectal interim analysis has moved earlier to around mid-2027 and breast cancer timing remains uncertain.
Sandra Pennell highlighted operating leverage: revenue rose to $35.1 million, gross margin was 89%, net income was $7 million, and adjusted EBITDA was $11.5 million. She noted R&D expense rose to $11 million due to more clinical headcount and trial activity, while SG&A increased to $13.1 million due to commercial expansion. She also pointed to $104.3 million in cash and investments, no debt, and $8.2 million of cash generated from operations, and said full-year 2026 guidance now calls for $115 million-$117 million in revenue, 87%-89% gross margin, and positive adjusted EBITDA.
Analysts focused on why Q3 beat expectations and why Q4 guidance implies a step down; management said the main reasons were stronger combination-therapy adoption, more patients asking for treatment, less clinical-trial disruption, and improved center staffing, while the Q4 conservatism mainly reflects holiday-related scheduling gaps and typical fourth-quarter seasonality. Questions also probed colorectal timing, and Gerard Michel moved the interim readout earlier to roughly Q2/Q3 next year. On 340B changes, he said the company expects a net neutral to net positive ASP impact with no volume effect, and on center expansion he said the pipeline of new sites is still active but variable.
The bull case from this call is that Delcath appears to be scaling a high-margin commercial product with strong cash generation and room to keep expanding the network. Management believes utilization is improving across both mature and new centers, and the raised guidance suggests the business is tracking ahead of prior expectations. The pipeline also offers additional upside, with colorectal progressing and new program planning underway for 2027.
The main risks are execution and timing: breast cancer enrollment has been slower than expected, and management would not give timing guidance for that interim analysis. Q4 guidance implies a sequential slowdown, which management attributes partly to holidays and seasonality, but it still shows the business is not linear. New center activations and treatment starts are also variable, and management acknowledged uncertainty around how many of the planned centers will actually launch by year-end.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.5%
- Shares Outstanding
- 34.79M
- Float Shares
- 32.18M
of shares held by institutions
131 13F filers
Buy/sell ratio 0.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for DCTH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Roger Wayne MarshallHouse · KS01 | Sell | Jun 9, 17 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.00M | ▲ 1.29M |
| Rosalind Advisors, Inc. | 3.30M | 0 |
| Vanguard Group Inc | 1.67M | ▲ 14.93K |
| Vanguard Capital Management LLC | 1.23M | ▲ 8.39K |
| Exoduspoint Capital Management, LP | 862.71K | ▲ 502.83K |
| Geode Capital Management, LLC | 822.90K | ▲ 89.79K |
| Algert Global LLC | 774.00K | ▲ 193.29K |
| State Street Corp | 759.94K | ▲ 80.66K |
| Millennium Management LLC | 608.02K | ▲ 41.65K |
| Propel Bio Management, LLC | 604.66K | ▼ 266.80K |
| Morgan Stanley | 550.56K | ▲ 142.57K |
| Marshall Wace, Llp | 371.89K | ▲ 152.93K |
Held by 139 ETFs
Biggest fund positions in DCTH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Martell Bridget A | other | 22,500 |
| Nov 12, 26 | Martell Bridget A | sell | 20,570 |
| Nov 12, 26 | Martell Bridget A | sell | 1,930 |
| Nov 12, 26 | Martell Bridget A | other | 22,500 |
| Oct 13, 26 | Rosalind Advisors, Inc. | other | 3,627 |
| Oct 13, 26 | Rosalind Advisors, Inc. | other | 27,502 |
| Oct 13, 26 | Rosalind Advisors, Inc. | other | 36.27 |
| May 13, 26 | Sylvester John Richard | other | 22,500 |
| May 13, 26 | Martell Bridget A | other | 22,500 |
| May 13, 26 | CZEREPAK ELIZABETH | other | 22,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DCTH coverage
Recent articles, reports, and earnings notes.
No research on DCTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DCTH report →Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 17
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
zacks.com · Nov 13
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
zacks.com · Nov 12
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 27.7%: Read This Before Placing a Bet
zacks.com · Nov 12
Delcath Systems to Be Featured on “Health Uncensored with Dr. Drew” in Segment Highlighting Advances in Liver-Directed Cancer Treatment
businesswire.com · Nov 11
Delcath Systems, Inc. (DCTH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Delcath Systems Q3 Earnings Call Highlights
marketbeat.com · Nov 9
Delcath Systems, Inc. (DCTH) Q3 Earnings and Revenues Top Estimates
zacks.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.